Magle Biopharma had the pleasure of hosting the concluding scientific seminar of the HyperTargIPS-NK project.

11/03/2026

Last week, Magle Biopharma had the pleasure of hosting the concluding scientific seminar of the HyperTargIPS-NK project, bringing together academic and industry partners to reflect on the scientific progress achieved during this ambitious EU‑funded collaboration.

The seminar showcased how close, interdisciplinary collaboration can accelerate innovation in cell‑based immunotherapies, covering progress across the full value chain, from platform development and functional characterization to translational and manufacturing considerations.

Key themes included:
Advances in iPSC‑derived NK cell platform development
Strategies to enhance cell functionality and persistence
Progress in genetic engineering approaches tailored to NK biology
Data from preclinical models
Early alignment with GMP and regulatory expectations to support future clinical translation

Beyond the science, the seminar highlighted the strength of the consortium and the importance of aligning research excellence with translational readiness from an early stage.

A big thank you to all speakers and partners from Lund University, Hannover Medical School, Københavns Universitet – University of Copenhagen, and Magle Biopharma for their engagement, openness, and scientific rigor throughout the project.

This collaboration demonstrates how European partnerships can drive impactful innovation in advanced therapies.